We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+38.76%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$170M
AUM Growth
+$48.4M
Cap. Flow
+$4.74M
Cap. Flow %
2.8%
Top 10 Hldgs %
66.82%
Holding
34
New
9
Increased
8
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$4.21M
2
PACB icon
Pacific Biosciences
PACB
+$3.43M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$3.41M
4
CDXS icon
Codexis
CDXS
+$3.08M
5
TSRO
TESARO, Inc.
TSRO
+$2.85M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.1M
2
BLUE
bluebird bio
BLUE
+$4.49M
3
ILMN icon
Illumina
ILMN
+$3.2M
4
KITE
Kite Pharma, Inc.
KITE
+$3.18M
5
CERN
Cerner Corp
CERN
+$3.08M

Sector Composition

Rank Sector Weight
1 Healthcare 88.88%
2 Materials 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
1
DELISTED
Sage Therapeutics
SAGE
$18.1M 10.69%
255,000
-4,500
-2% -$264K
FMI
2
DELISTED
Foundation Medicine, Inc.
FMI
$15.5M 9.13%
480,000
-66,000
-12% -$1.65M
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
$15.1M 8.94%
360,000
– –
AGIO icon
4
Agios Pharmaceuticals
AGIO
$1.84B
$13.9M 8.18%
237,500
-3,000
-1% -$144K
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$11.8M 6.95%
294,500
+50,000
+20% +$1.79M
EVH icon
6
Evolent Health
EVH
$359M
$11.6M 6.84%
520,000
-35,000
-6% -$672K
EPZM
7
DELISTED
Epizyme, Inc
EPZM
$8.32M 4.91%
485,000
+210,000
+76% +$2.8M
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$7.2M 4.25%
135,000
+6,500
+5% +$386K
VYGR icon
9
Voyager Therapeutics
VYGR
$179M
$6.62M 3.91%
500,000
+115,000
+30% +$1.4M
GNMK
10
DELISTED
GenMark Diagnostics, Inc
GNMK
$5.13M 3.03%
400,000
-110,000
-22% -$1.32M
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
$4.43M 2.61%
+260,000
New +$4.21M
SGMO
12
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.42M 2.61%
+850,000
New +$3.41M
MDRX
13
DELISTED
Veradigm Inc. Common Stock
MDRX
$3.93M 2.32%
310,000
+30,000
+11% +$356K
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.74M 2.21%
101,500
-202,500
-67% -$5.1M
PACB icon
15
Pacific Biosciences
PACB
$444M
$3.62M 2.14%
+700,000
New +$3.43M
MYOK
16
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$3.48M 2.06%
265,000
– –
KITE
17
DELISTED
Kite Pharma, Inc.
KITE
$3.34M 1.97%
42,500
-51,500
-55% -$3.18M
CDXS icon
18
Codexis
CDXS
$158M
$3.24M 1.91%
+675,000
New +$3.08M
AMRS
19
DELISTED
Amyris Inc.
AMRS
$3.18M 1.88%
400,000
+171,667
+75% +$1.46M
CTMX icon
20
CytomX Therapeutics
CTMX
$686M
$3.06M 1.81%
177,500
+50,000
+39% +$658K
EDIT icon
21
Editas Medicine
EDIT
$399M
$2.98M 1.76%
133,333
+68,333
+105% +$1.42M
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.9M 1.71%
18,214
– –
JNCE
23
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.86M 1.69%
+130,000
New +$2.75M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$29.1B
$2.82M 1.66%
55,000
-30,000
-35% -$1.39M
TSRO
25
DELISTED
TESARO, Inc.
TSRO
$2.69M 1.59%
+17,500
New +$2.85M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Casdin Capital held 34 positions worth $170M, up 40% from $121M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Casdin Capital's Q1 2017 filing shows 9 new, 8 increased, 9 reduced and 5 closed positions. Its largest new stake was Audentes Therapeutics, Inc: 260,000 shares worth $4.43M. The largest sale was Global Blood Therapeutics, Inc., an estimated $5.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 81% a quarter earlier, followed by Materials.

  • Casdin Capital's largest Q1 2017 buy was Audentes Therapeutics, Inc: 260,000 shares worth $4.43M.
  • Casdin Capital added most to Epizyme, Inc in Q1 2017, an estimated $2.8M increase.
  • Casdin Capital's biggest Q1 2017 reduction was Global Blood Therapeutics, Inc., cutting an estimated $5.1M.
  • Casdin Capital fully exited Illumina in Q1 2017, selling an estimated $3.2M.
  • Casdin Capital's ten largest holdings make up 67% of its $170M portfolio in Q1 2017.
  • Casdin Capital opened 9 new positions and closed 5 in Q1 2017.
  • Casdin Capital's portfolio value rose 40% quarter-over-quarter to $170M.

Based on Casdin Capital's 13F filing for Q1 2017, filed 15 May 2017.